RU-58841 is an experimental nonsteroidal antiandrogen that was investigated for topical treatment of androgenetic alopecia in the 1990s. Development was discontinued before completing human safety trials. It has never been approved for human use. This page presents what limited research exists — primarily animal studies — with appropriate caution about the substantial unknowns.
RU-58841 (chemical name: 4-(4-Hydroxy-3-trifluoromethylphenylamino)-2-methylpropanamido-2-cyanopropanamide) is a nonsteroidal antiandrogen designed for topical application. Unlike finasteride, which blocks DHT production, RU-58841 is intended to block the androgen receptor (AR) directly at the follicle level, preventing DHT from exerting its miniaturizing effects.
RU-58841 competes with DHT for binding to androgen receptors in hair follicles. By occupying the receptor, it blocks DHT's ability to trigger follicle miniaturization. This is a different mechanism than 5α-reductase inhibitors like finasteride.
The compound was designed for topical use with minimal systemic absorption. Animal studies suggested limited bioavailability when applied to skin — meaning effects should be local, not systemic. However, this was never confirmed in human pharmacokinetic studies.
In animal studies, RU-58841 showed rapid degradation in blood plasma, suggesting that any systemic absorption would be quickly metabolized. Human pharmacokinetics are unknown.
The metabolic pathway of RU-58841 in humans is not established. Unknown metabolites could have their own biological activity — including potential harmful effects not detected in short-term animal studies.
The evidence for RU-58841 is primarily from animal studies conducted in the 1990s by the original developer (Roussel-Uclaf) and subsequent academic researchers. Human clinical data is extremely limited. We present this evidence with appropriate caveats about its quality and applicability.
🔴 Evidence quality: Very Low. No randomized controlled trials in humans. One small pilot study (n=20). Mostly animal data. Development abandoned before Phase 2 trials. Unknown reasons for discontinuation.
The primary evidence comes from studies on stump-tailed macaques (a primate model of androgenetic alopecia) conducted in the 1990s:
Critical limitation: Macaque results don't necessarily translate to humans. Many compounds that work in animals fail in human trials.
There is no established human dosing for RU-58841 because it has never been approved or completed clinical trials. The following represents what is commonly reported in online communities — not recommendations. We include this for educational completeness only.
Some vendors sell pre-mixed solutions. Concentration and purity cannot be independently verified.
Some users purchase raw powder and mix their own solutions. This introduces additional risks: inaccurate dosing, contamination, degradation.
⚠️ Purity and contamination concerns: RU-58841 is sold by unregulated vendors as a "research chemical." Purity claims cannot be verified. Batches may contain contaminants, degradation products, or be mislabeled. There is no quality control equivalent to pharmaceutical standards.
Understanding how RU-58841 compares to proven treatments helps contextualize why approved options remain the recommended first-line approach.
The following side effects are reported in online communities. These are not verified by controlled studies and may represent coincidence, nocebo effect, or unrelated conditions. The actual safety profile of RU-58841 is unknown.
🔴 Unknown unknowns: The most concerning aspect of RU-58841 is what we don't know. Long-term cardiovascular effects? Carcinogenic potential? Endocrine disruption? Liver toxicity? None of these have been evaluated in human studies. Using an abandoned pharmaceutical with unknown safety is inherently high-risk.
Development history: RU-58841 was developed by Roussel-Uclaf (French pharmaceutical company, later merged with Hoechst/Sanofi) in the late 1980s–early 1990s. It progressed through preclinical and early Phase 1/2 human trials before being discontinued.
Why was it abandoned? The exact reasons are not public. Possible explanations include:
Current legal status: RU-58841 is not a controlled substance in most countries. It exists in a legal gray zone — sold as a "research chemical" not intended for human use. Purchasing and self-administering it may carry legal and health risks depending on jurisdiction.
The following are the primary scientific publications on RU-58841. Note the limited scope and age of this research.
Uno H, et al. "The stumptailed macaque as a model for baldness: effects of minoxidil." Int J Cosmet Sci 1998. Compared RU-58841 to minoxidil in macaque model.
PubMed: 18505480 →Battmann T, et al. "RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism." J Steroid Biochem Mol Biol 1994;48:55-60.
PubMed: 8136308 →Cousty-Berlin D, et al. "Preliminary study of the local antiandrogen action of RU 58841 in the stumptailed macaque." Roussel-Uclaf internal research. Demonstrated AR antagonism in vivo.
PubMed: 7945019 →De Brouwer B, et al. "Pharmacokinetics and metabolism of RU 58841 in rats." Drug Metab Dispos 1994. Animal PK data showing rapid clearance.
PubMed: 7834878 →📚 Note: All published research is from 1994-1998 — over 25 years old. No human efficacy trials were ever published. Any information about human trials is from company press releases or regulatory filings, not peer-reviewed publications.
We recommend FDA-approved treatments with established safety profiles. The following are complementary products for proven hair loss protocols.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
🔴 IMPORTANT DISCLAIMER: RU-58841 is an unapproved research chemical that was abandoned during pharmaceutical development for unknown reasons. It has never completed human safety trials. Long-term cardiovascular, endocrine, and carcinogenic effects are completely unknown.
This page is for educational purposes only. We do NOT recommend, endorse, or encourage the use of RU-58841. FDA-approved alternatives (finasteride, minoxidil) have established efficacy and known safety profiles.
Anyone considering RU-58841 should understand they are assuming unknown risks with an untested compound sold by unregulated vendors. Consult a dermatologist for evidence-based hair loss treatment.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.